With ObesityWeek and EASD 2026 approaching, this update covers the latest NHS tirzepatide data, the NICE lower BMI threshold timeline, the UKCO 2026 programme, and a progress update on the semaglutide MASH MHRA review.

---

NHS Tirzepatide — 8-Month Data

• Cumulative patients: 220,000
• Prescribing rate: 9,500 new patients per week (stable)
• 6-month outcomes (n=24,800 with 6-month data): Mean weight loss 13.2%; ≥10% weight loss 62%; ≥15% weight loss 28%

Equity update: The proportion of patients from the most deprived quintile has risen to 33% (vs 28% at month 1), suggesting continued improvement in equitable access.

Prescribing by region: Significant variation persists between ICBs (prescribing rates range from 180 to 420 patients per 100,000 population). NHS England has written to the 8 lowest-prescribing ICBs requesting improvement plans.

---

NICE — Lower BMI Threshold Guidance: Timeline Update

NICE has confirmed that the final guidance on lower BMI thresholds for obesity pharmacotherapy will be published in October 2026. If the final guidance confirms the draft proposal, an estimated additional 400,000 people in England would become eligible for obesity pharmacotherapy.

---

UKCO 2026 — Programme Announced

The UK Congress on Obesity 2026 will be held in Manchester, 20–21 November 2026. Theme: "Obesity in the Era of Effective Pharmacotherapy."

Key sessions:

• "One year of NHS tirzepatide: what have we learned?" — NHS England
• "Retatrutide Phase 3 data: implications for UK practice" — Professor John Wilding
• "Orforglipron: the oral revolution — when will it reach UK patients?"
• "Equity in obesity care: progress and persistent gaps"

Registration opens 1 October 2026.

---

Semaglutide MASH — MHRA Review Update

The MHRA has confirmed that its review of the semaglutide 2.4 mg MASH indication is progressing on schedule, with a decision expected in mid-2027. If approved, NICE has indicated that it will begin a rapid appraisal of the MASH indication.

---

Pipeline Watch — ObesityWeek 2026 Preview

With ObesityWeek 2026 opening in Denver on 12 October, the following data presentations are anticipated:

• Retatrutide TRIUMPH-1 and TRIUMPH-2: Primary Phase 3 data
• CagriSema REDEFINE-4: Cardiovascular outcomes interim data
• AMG 133: Updated Phase 2b data with 72-week follow-up
• NHS tirzepatide: 8-month real-world outcomes (UK presentation)

---

This update is prepared for UK healthcare professionals. All prescribing decisions should reference current NICE guidance, the BNF, and individual patient clinical assessment.